Nebi Serkan Demirci1, Sercan Aksoy2, Nuriye Yıldırım Özdemir3, Gökmen Umut Erdem1, Melike Ozcelik4, Eda Tanrikulu5, Tülay Eren6, Yakup Bozkaya1, Süleyman Sahin6, Fatma Başol7, Suheyla Aytac Aslan8, Nurullah Zengin1, İbrahim Güllü2. 1. a Ankara Numune Training and Research Hospital , Department of Medical Oncology , Ankara , Turkey. 2. b Hacettepe University, Cancer Institute , Department of Medical Oncology , Ankara , Turkey. 3. c Yıldırım Beyazıt University Faculty of Medicine , Department of Medical Oncology , Ankara , Turkey. 4. d Kartal Dr. Lutfi Kirdar Training and Research Hospital , Department of Oncology , Istanbul , Turkey. 5. e Marmara University Faculty of Medicine , Department of Oncology , Istanbul , Turkey. 6. f Dıskapı Training And Research Hospital , Department of Medical Oncology , Ankara , Turkey. 7. g Ankara Oncology Research and Training Hospital , Department of Medical Oncology , Ankara , Turkey. 8. h Yıldırım Beyazıt University Faculty of Medicine , Department of Radiation Oncology , Ankara , Turkey.
Abstract
AIM: Modified docetaxel, cisplatin, and 5-fluorouracil (mDCF) therapy has been shown to be a well tolerated and highly effective regimen for metastatic gastric carcinoma. Herein we investigated the effectiveness of the mDCF combination as the first-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (HNSCC). METHODS: A total of 80 patients with recurrent/metastatic HNSCC who were treated with mDCF between 2009 and 2015 were enrolled into this study. All patients were treated in the first-line with 2-6 cycles of mDCF chemotherapy which consisted of docetaxel 60 mg/m2 intravenously (IV) on day 1, cisplatin 60 mg/m2 IV on day 1, and 5-fluorouracil 600 mg/m2 IV for 5 days of continuous infusion, with cycles repeated every 21 days. RESULTS: The most common grade 3-4 toxicities were neutropenia (22.5%), anemia (10%), thrombocytopenia (7.5%), nephrotoxicity (1.3%), hepatotoxicity (1.3%), and diarrhea (2.5%). Twelve patients (15%) experienced a febrile neutropenic episode. Dose modification was required in 22 (27.5%) of the patients due to drug toxicity. Complete response was achieved in 2.5% of all patients, while partial and stable responses were reported to be 43.8% and 25%, respectively, with a disease control rate of 71.3%. The median progression-free and overall survival was 7 (95% CI: 5.3-8.6) and 11.5 (95% CI: 9.4-13.7) months, respectively. CONCLUSIONS: The efficiency of the mDCF combination for induction chemotherapy has been well established previously. To our knowledge, this is one of the largest studies evaluating the survival and safety significance of mDCF chemotherapy as a first-line treatment in patients with recurrent/metastatic HNSCC.
AIM: Modified docetaxel, cisplatin, and 5-fluorouracil (mDCF) therapy has been shown to be a well tolerated and highly effective regimen for metastatic gastric carcinoma. Herein we investigated the effectiveness of the mDCF combination as the first-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (HNSCC). METHODS: A total of 80 patients with recurrent/metastatic HNSCC who were treated with mDCF between 2009 and 2015 were enrolled into this study. All patients were treated in the first-line with 2-6 cycles of mDCF chemotherapy which consisted of docetaxel 60 mg/m2 intravenously (IV) on day 1, cisplatin 60 mg/m2 IV on day 1, and 5-fluorouracil 600 mg/m2 IV for 5 days of continuous infusion, with cycles repeated every 21 days. RESULTS: The most common grade 3-4 toxicities were neutropenia (22.5%), anemia (10%), thrombocytopenia (7.5%), nephrotoxicity (1.3%), hepatotoxicity (1.3%), and diarrhea (2.5%). Twelve patients (15%) experienced a febrile neutropenic episode. Dose modification was required in 22 (27.5%) of the patients due to drug toxicity. Complete response was achieved in 2.5% of all patients, while partial and stable responses were reported to be 43.8% and 25%, respectively, with a disease control rate of 71.3%. The median progression-free and overall survival was 7 (95% CI: 5.3-8.6) and 11.5 (95% CI: 9.4-13.7) months, respectively. CONCLUSIONS: The efficiency of the mDCF combination for induction chemotherapy has been well established previously. To our knowledge, this is one of the largest studies evaluating the survival and safety significance of mDCF chemotherapy as a first-line treatment in patients with recurrent/metastatic HNSCC.
Entities:
Keywords:
Cisplatin; docetaxel; fluorouracil; head and neck cancer; metastasis; modified DCF; recurrence
Authors: Manon Launay; Joseph Ciccolini; Claire Fournel; Carmelo Blanquicett; Charlotte Dupuis; Nicolas Fakhry; Florence Duffaud; Sébastien Salas; Bruno Lacarelle Journal: Clin Cancer Drugs Date: 2017